View Older Stories View More Recent Stories

Mar 26, 2026 08:41AM Lucid Diagnostics Inc. (LUCD) Misses Q4 EPS by 1c
Mar 26, 2026 08:02AM Lucid Diagnostics reports Q4 revenue of $1.5 million, secures VA contract
Mar 26, 2026 06:54AM Canaccord Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
Mar 26, 2026 06:08AM Lucid Diagnostics Inc (LUCD) files $175M mixed shelf
Feb 4, 2026 08:04AM PAVmed raises $45 million, eliminates convertible securities overhang
Dec 10, 2025 03:54AM Lucid Diagnostics Inc (LUCD) PT Raised to $8.25 at Ascendiant Capital
Dec 9, 2025 08:03AM Lucid Diagnostics reports real-world data from 12,000 esophageal tests
Nov 13, 2025 04:46AM Needham Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
Nov 12, 2025 05:16PM Lucid Diagnostics Inc. (LUCD) Tops Q3 EPS by 1c
Sep 10, 2025 12:24PM BTIG on Lucid Diagnostics Inc (LUCD): 'Lucid is in very early innings addressing a large unmet need'
Sep 5, 2025 06:02AM Needham Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
Sep 5, 2025 05:32AM Canaccord Genuity on Lucid Diagnostics Inc (LUCD): 'we believe the stock does not reflect the company's long-term growth potential'
Sep 5, 2025 05:30AM Lucid Diagnostics Inc (LUCD) PT Raised to $2.50 at BTIG
Aug 20, 2025 06:35AM BTIG Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
Aug 19, 2025 07:07AM Cantor Fitzgerald Reiterates Overweight Rating on Lucid Diagnostics Inc (LUCD)
Aug 13, 2025 08:03AM Lucid Diagnostics Inc. (LUCD) Tops Q2 EPS by 1c
Jul 30, 2025 08:02AM PAVmed gets 180-day extension from NASDAQ to meet $1 minimum bid price
Jun 6, 2025 05:25AM Lucid Diagnostics Inc (LUCD) PT Raised to $7.75 at Ascendiant Capital
May 27, 2025 07:31AM Lucid Diagnostics Inc (LUCD) to Join Russell 2000 and Russell 3000 Indexes
May 19, 2025 06:43AM Cantor Fitzgerald Reiterates Overweight Rating on Lucid Diagnostics Inc (LUCD)
May 14, 2025 04:47PM Lucid Diagnostics Inc. (LUCD) Tops Q1 EPS by 3c
May 14, 2025 04:38PM Cantor Fitzgerald Reiterates Overweight Rating on Lucid Diagnostics Inc (LUCD)
Apr 11, 2025 09:26AM Lucid Diagnostics (LUCD) Announces Closing of Public Offering of Common Stock
Apr 9, 2025 04:01PM Lucid Diagnostics (LUCD) Announces Proposed Public Offering of Common Stock
Mar 26, 2025 06:46AM Cantor Fitzgerald Reiterates Overweight Rating on Lucid Diagnostics Inc (LUCD)
Mar 25, 2025 05:53AM Lucid Diagnostics Inc (LUCD) PT Lowered to $2 at BTIG
Mar 24, 2025 02:32PM Canaccord Genuity Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
Mar 24, 2025 12:43PM Lucid Diagnostics Inc (LUCD) PT Raised to $3 at Needham
Mar 24, 2025 08:05AM Lucid Diagnostics Inc. (LUCD) Misses Q4 EPS by 2c
Mar 20, 2025 12:23PM Needham on Lucid (LUCD): 'we remain positive on potential Medicare reimbursement of EsoGuard and we expect LUCD's revenue growth to improve'
Mar 17, 2025 07:38AM Cantor Fitzgerald newsletter says Elutia best, Anteris worst performer
Mar 13, 2025 07:37AM Lucid Diagnostics Inc (LUCD) Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard Esophageal DNA Test
Mar 5, 2025 04:45PM Lucid Diagnostics Inc (LUCD) Closes $15.3M Direct Offering
Mar 4, 2025 08:25AM Lucid Diagnostics Inc (LUCD) Prices 13.94M Share Offering at $1.10/sh
Feb 27, 2025 08:36AM Lucid Diagnostics Inc (LUCD): Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard in At-Risk Patients without Symptomatic GERD
Feb 25, 2025 08:31AM Lucid Diagnostics (LUCD) Regains Compliance with Nasdaq Minimum Bid Price Requirement
Feb 20, 2025 08:31AM Lucid Diagnostics Inc (LUCD) Executes First Concierge Medicine Contract with LEAA Health
Feb 18, 2025 08:31AM PAVmed (PAVM) Regains Compliance with Nasdaq Stockholders' Equity Requirement
Jan 13, 2025 08:00AM Lucid Diagnostics (LUCD) Announces Record Quarterly EsoGuard Test Volume
Dec 23, 2024 08:02AM Lucid Diagnostics Inc (LUCD) Granted Nasdaq Extension to Regain Compliance
Nov 15, 2024 06:41AM Lucid Diagnostics Inc (LUCD) PT Lowered to $2 at Cantor Fitzgerald
Nov 13, 2024 12:31PM Needham Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
Nov 5, 2024 08:03AM Lucid Diagnostics (LUCD) Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers
Oct 15, 2024 07:51AM Lucid Diagnostics (LUCD) Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test
Oct 14, 2024 06:38AM BTIG Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
Sep 16, 2024 04:30PM PAVmed (PAVM) Announces Efforts to Regain Nasdaq Compliance
Sep 3, 2024 07:52AM Lucid Diagnostics Inc (LUCD) Signs MoU with Front Line Mobile Health
Aug 20, 2024 08:16AM Lucid Diagnostics (LUCD) Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer
Aug 13, 2024 02:57PM Cantor Fitzgerald Positive on Lucid Diagnostics Inc (LUCD) Following Earnings
Aug 13, 2024 08:27AM Lucid Diagnostics Inc (LUCD): American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer
View More Recent Stories View Older Stories